Research overview
Klow Blend: what the research shows
What is the Klow Blend?
The Klow Blend is a single lyophilized vial containing four research peptides: BPC-157, TB-500, the copper peptide GHK-Cu, and the tripeptide KPV. It adds KPV to the three peptides in our Glow Blend. Each component has its own page: BPC-157, TB-500, GHK-Cu, and KPV.
Research on this specific four-peptide combination in one vial is limited. The work summarized below was done on each peptide individually. This page makes no claim that the four components interact, add to one another, or produce a combined effect.
| Component 1: BPC-157 | GEPPPGKPADDAGLV, 15 amino acids, C62H98N16O22, 1419.5 g/mol (PubChem CID 9941957) |
|---|---|
| Component 2: TB-500 | Indexed by PubChem as Ac-LKKTETQ, the acetylated 17-23 fragment of thymosin beta-4, C38H68N10O14, 889.0 g/mol (PubChem CID 62707662) |
| Component 3: GHK-Cu | Copper(II) complex of the tripeptide Gly-His-Lys (GHK); GHK peptide C14H24N6O4, 340.38 g/mol (PubChem CID 73587) |
| Component 4: KPV | Lys-Pro-Val, alpha-MSH (11-13), C16H30N4O4, 342.43 g/mol (PubChem CID 125672) |
| Form | Lyophilized powder, four peptides combined in a single vial |
| Labeled strength | 50/10/10/10mg |
The four components
BPC-157
A synthetic 15-residue fragment of a protein first isolated from human gastric juice [1]. In rat tendon fibroblasts it increased migration and survival, linked to focal adhesion kinase and paxillin phosphorylation [5]. A 2025 systematic review found the evidence almost entirely preclinical and concluded the peptide should be regarded as investigational [6].
TB-500
PubChem indexes TB-500 as Ac-LKKTETQ, an acetylated copy of residues 17 to 23 of the actin-binding protein thymosin beta-4 [2], although the name is also used for synthetic full-length thymosin beta-4. A 2010 review associated the LKKTETQ region of the parent protein with angiogenesis, wound healing, and cell migration in experimental systems [7]. Findings for the full protein cannot automatically be attributed to the fragment; see the TB-500 page.
GHK-Cu
GHK (glycyl-L-histidyl-L-lysine) is a copper-binding tripeptide isolated from human plasma [3] [8]. Its copper complex stimulated collagen synthesis in fibroblast cultures in a 1988 study [8]. Our article on GHK-Cu peptide research covers the wider literature.
KPV
KPV is the C-terminal tripeptide (residues 11 to 13) of alpha-melanocyte-stimulating hormone [4]. In human intestinal epithelial and T-cell lines, KPV entered cells through the PepT1 transporter and inhibited NF-kappaB and MAP kinase inflammatory signaling; in mice it reduced the incidence of chemically induced colitis [9]. A 2008 review explained that KPV drew interest because it retained anti-inflammatory activity in experimental systems without the pigmentary action of the full hormone [10]. FDA reports no human exposure data for KPV products [12].
What is known about the combination
We did not find published research on these four peptides together, or on KPV combined with any of the other three. The only combination data we found involve two of the components: a 2026 rat Achilles tendon study compared BPC-157, TB-500, and both together, and the authors reported no additional effect in the combined group over either peptide alone [11]. That study did not include GHK-Cu or KPV, and did not use a pre-combined vial.
The four components were studied in different model systems, for different endpoints, by different research groups. Nothing in that literature describes how they behave stored together, and human evidence is very limited or absent for each [6] [12]. The findings above should not be read as evidence of safety or benefit in people.
See also our BPC-157 research overview and other research peptides in this category.
Regulatory status
- Not FDA approved. BPC-157, TB-500, and KPV are unapproved peptides, not FDA-approved drugs [13], and this blend is not an approved drug.
- Compounding. FDA's list of bulk drug substances that may present significant safety risks (current as of April 22, 2026) places all four components among withdrawn nominations: BPC-157, the thymosin beta-4 fragment known as TB-500, KPV, and GHK-Cu (for certain routes of administration). FDA notes limited or missing human safety information for each [12].
- Advisory committee vote. In July 2026, FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with 1 abstention, to recommend each of BPC-157, TB-500, and KPV for the 503A bulks list, against FDA staff's recommendation. GHK-Cu was not reviewed at that meeting. The votes are non-binding, and FDA had not acted on them at the time of this review [13] [14].
- Sport. The World Anti-Doping Agency 2026 Prohibited List names BPC-157 under S0 and "Thymosin-β4 and its derivatives e.g. TB-500" under S2.3 [15].
Rejuvatide supplies the Klow Blend strictly as a research chemical for in vitro and laboratory use. It is not sold for human or veterinary use.
Testing and quality
The Klow Blend has its own certificate from an independent laboratory. It reports HPLC purity of the combined material, confirms the identity of all four components (GHK-Cu, KPV, TB-500, and BPC-157) by LC-MS, and includes an endotoxin result under USP <85>. The certificate is shown below and in our COA library, published exactly as the laboratory issued it.
Storage of lyophilized material
The Klow Blend ships as a lyophilized (freeze-dried) powder, which is stable at ambient temperature during transit. For long-term storage, keep sealed vials at -20°C, protected from light and moisture. Allow a vial to reach room temperature before opening to limit condensation. Handling of any prepared solutions should follow your laboratory's own validated procedures.